CIS interventional cardiologist, Dr. Robert Menuet II, was the first to use the TRYTON Side Branch Stent to treat coronary artery disease at Opelousas General Health System.
The flexible new stent technology is specially designed to fit the shape of a blocked main heart artery that also has a blockage located in the side branch of the heart. It is delivered to the artery via a balloon delivery catheter and is used in conjunction with a conventional drug-eluding stent implanted in the main vessel. Stenting of the main branch is the current standard of care, but in many cases the side branch is not stented, leaving it vulnerable to complications, such as future blockages leading to emergency stent placement.
“The Tryton stent technology allows patients with complicated artery blockages to avoid bypass surgery and have an outpatient procedure in the cath lab where they can go home that day,” said Dr. Menuet. “It’s one of the most advanced technologies in fixing these types of blockages, and we are proud to offer it to the Opelousas community.”
Coronary artery disease, the leading cause of death in the U.S. in both men and women, often results in the buildup of plaque at a site where one artery branches from another, also known as a bifurcation. Approximately 20-30% of all patients undergoing percutaneous coronary interventions to open blocked arteries have a bifurcation lesion.
The TRYTON Side Branch Stent is a cobalt chromium stent based on Tri-ZONE® technology engineered to provide complete lesion coverage and more predictable patient outcomes. In February 2017, the TRYTON Side Branch Stent became the first dedicated bifurcation stent to receive regulatory approval in the U.S. It is manufactured by Tryton Medical and distributed by Cordis. For more information, visit https://www.cordis.com/en_us/cmp/ext/tryton-side-branch-stent.html.